Translational Pharmaceutics and the Benefits of Real-Time Adaptive Manufacturing
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
Awards
Quotient Sciences is delighted to be selected as the winner of the Outstanding Achievement award at last night’s Medilink East Midlands Business Awards. The Outstanding Achievement award recognizes organizations which have celebrated momentous success or development.
Event
We will be exhibiting at the Outsourced Pharma Conference and Exhibition in San Francisco on 29-30 October.
Fact Sheet
From preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.
Scientific Posters
Deutetrabenazine (Austedo, Teva) is approved for the treatment of chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD). Deutetrabenazine is the first deuterated product approved by the FDA and only the second product approved in HD and TD. Deutetrabenazine is a novel VMAT2 inhibitor that is structurally related to tetrabenazine, with two trideuteromethoxy groups at the 9- and 10-positions in tetrabenazine
